Edgar Filing: Thompson Peter A. - Form 4

Thompson Form 4											
July 05, 20	11										
FORM	V 4 UNITED	STATES S	SECURI	TIES A	AND EX	CHANGE	COMMISSION		APPROVAL		
Check t	his hoy		Wash	ington	, D.C. 2	0549		Number:	3235-0287		
if no los subject Section Form 4	nger to STATE 16.	MENT OF (F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Estimated burden hou	Expires: January 31 2005 Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Thompson Peter A.			2. Issuer Name and Ticker or Trading Symbol Anthera Pharmaceuticals Inc [ANTH]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
											(Last)
INC., 2580	HERA CEUTICALS,)1 INDUSTRIAL ARD, SUITE B		06/30/20	11				,			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			al	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
HAYWAR	RD, CA 94545						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Table	I - Non-l	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ate, if T C		4. Securi onAcquirec Disposec (Instr. 3,	l (A) or l of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect		
			C	ode V	Amount	(D) Price	(Instr. 5 and 4)				
Reminder: Re	eport on a separate lin	e for each class	s of securi	ties bene	Perse infor requi	ons who res mation con red to resp ays a curre	or indirectly. spond to the colle tained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Thompson Peter A. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 8.17	06/30/2011		А	12,000	(1)	04/18/2021	Common Stock	12,000
Stock Option (right to buy)	\$ 8.17	06/30/2011		A	25,000	(2)	04/18/2021	Common Stock	25,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
FB	Director	10% Owner	Officer	Other		
Thompson Peter A. C/O ANTHERA PHARMACEUTICALS, INC. 25801 INDUSTRIAL BOULEVARD, SUITE B HAYWARD, CA 94545	Х					
Signatures						
/s/ Bradley A. Bugdanowitz, by power of attorney Thompson		07/05/2011				
**Signature of Reporting Person				Date		
Evalenction of Decrements						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests and becomes exercisable in equal monthly installments over a one-year period from April 19, 2011.
- (2) This option vests over a four-year period, with one-quarter of the underlying shares vesting on February 1, 2012 and the remainder vesting in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S ()